Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases
01 May 2024 - 10:00PM
Creyon Bio, Inc. ("Creyon"), a drug development company that
engineers Oligonucleotide-Based Medicines (OBMs) with industry
leading efficiency creating novel, best-in-class gene-centric
medicines to treat rare and common diseases, and Cajal
Neuroscience, ("Cajal"), a biotechnology company integrating
disease-focused genetics and human data with state-of-the-art
experimental capabilities to discover novel targets and
therapeutics for neurodegeneration, today announced a partnership
to develop novel OBMs for neurodegenerative diseases.
Under the collaboration, the companies are developing antisense
oligonucleotides (ASOs) for multiple neurodegenerative diseases.
Cajal is responsible for nominating targets and mechanisms of
action based on therapeutic insights from their discovery platform.
Creyon is responsible for engineering oligonucleotide therapeutic
candidates leveraging the powerful Creyon™ Platform, the first and
only OBM platform designed to engineer for safety first, creating
lead compounds with optimal pharmacological properties designed to
minimize side effects. Cajal will complete validation and
IND-enabling studies of the lead therapeutic candidates. Creyon and
Cajal have initiated and successfully advanced multiple programs,
including one program nearing IND-enabling studies.
Chris Hart, Ph.D., Co-Founder, Chief Executive Officer, and
President of Creyon Bio, said, “We are well positioned to
accelerate the development of much needed therapies for patients
with common neurodegenerative disorders by combining Cajal's target
identification capabilities with our platform designed to engineer
safe, effective, and ultimately best-in-class compounds. This
synergy between innovative target discovery capabilities and expert
engineering of oligonucleotide-based medicines illustrates the
strategic value of collaboration to advance new treatments for a
myriad of diseases where there is high unmet need.”
“Oligonucleotides offer a promising modality for treating
diseases of the central nervous system, including neurodegenerative
disease. Using our human genetics platform we have identified novel
targets that are well suited to oligonucleotide therapeutics.
Creyon’s expertise in developing ASOs has been instrumental in our
ability to prosecute on the targets we have identified. We look
forward to continuing the collaboration as new targets continue to
emerge from our platform,” said Ian Peikon, Ph.D., & Andrew
Dervan, M.D., Co-Founders & Co-Chief Executive Officers of
Cajal Neuroscience.
About Creyon Bio, Inc.Creyon Bio is a clinical
stage biotechnology company developing best-in-class precision
medicines with industry-leading efficiency through molecular
engineering of Oligonucleotide-Based Medicines (OBMs). This
includes ASOs, siRNAs, and aptamers. The company is changing how we
create novel OBMs, transforming the process from drug discovery to
drug engineering. Creyon has built the first and only platform
capable of engineering for safety first, translating new target
discoveries to OBMs with optimal pharmacological properties.
Coupled with our aptamer-based delivery technologies, Creyon Bio is
unlocking the full potential of OBMs for common and rare diseases
alike. To learn more, visit creyonbio.com.
About Cajal NeuroscienceCajal Neuroscience is a
biotechnology company committed to developing therapeutics for
neurodegenerative diseases. Cajal is focused on identifying genetic
modifiers of disease progression and translating them into novel
therapeutics for neurodegeneration. Cajal leverages an integrated
platform that layers genetics with human multi-omics, longitudinal
clinical data, and high-throughput biology. Cajal has built a
pipeline of therapeutics based on genetic discoveries into the
molecular drivers of disease progression, with an initial focus on
Parkinson’s and Alzheimer’s disease. Cajal is headquartered in
Seattle, WA.
Creyon Bio Media ContactJon
YuCreyonPR@westwicke.com
Cajal Neuroscience Media
Contactmedia@cajalneuro.com